Navigation Links
New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
Date:9/11/2008

EXTON, Pa., Sept. 11 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the release of TreatmentTrends(TM): Anemia Managers. This is the first report in a series conducted with Anemia Managers. It is based on the results of an on-line survey completed by 150 Anemia Managers -- 100 working with dialysis patients and 50 working with later stage Chronic Kidney Disease (CKD) patients, and qualitative interviews with a subset of 25 respondents. The report focuses on the management of renal anemia, including the use of ESAs and IV iron. Comparisons to Nephrologist responses regarding anemia management are made throughout the report, based on data from the recently published BioTrends TreatmentTrends(TM): Nephrology report.

In the dialysis market, Anemia Managers are very involved in monitoring lab values related to ESA and IV iron use and making therapy decisions based on labs and protocols. Similar to Nephrologists, the vast majority of Anemia Managers report that ESA safety issues have impacted their use of ESAs in dialysis. Both Anemia Managers and Nephrologists most often report protocol changes and ESA dose reductions at lower hemoglobin levels as types of changes, but Anemia Managers were more likely to report that they are using lower average doses of ESAs, monitoring hemoglobins more frequently, and placing more emphasis on a patient's IV iron status. Relatedly, Anemia Managers predict a significant increase in their use of IV iron in the next three months, and over one-third report changing their IV iron protocol in the past three months -- most often allowing higher levels of ferritin before holding IV iron and making more effort to keep patients on maintenance therapy (by extending dosing frequency, for example) instead of discontinuing therapy. American Regent's Venofer is the market share leader in the hemodialysis market over Watson's Ferrlecit.

In the CKD market, similar to the dialysis market, Anemia Managers are often in charge of monitoring lab values and adjusting treatment based on protocols for both ESAs and IV iron. In CKD, however, Anemia Managers tend only to see the patients who Nephrologists deem are in need of anemia management. The nephrology office or CKD clinic is the most common place patients receive their ESA therapy. For patients who do not receive their ESA at the office, administration location is typically driven by geography or insurance. From a brand perspective, Amgen's Aranesp and Ortho-Biotech's Procrit continue to battle for market leadership in CKD. Anemia Managers tend to feel that Procrit has an advantage on tolerability, ease of dosing modifications, and reimbursement, whereas Aranesp has an advantage for patients who self-inject. IV iron is used with much less frequency in CKD patients compared to ESAs; however, Anemia Managers predict a significant increase in their use of IV iron in the next three months. Potential reasons include an increased focus by managed care on iron status to approve ESAs and restrictions on starting ESAs (often Hb less than or equal to 10g/dL). For CKD patients who do receive IV iron, most do so on a repletion basis, commonly 1000mg over five infusions. The most desired feature in a new IV iron product among Anemia Managers working with CKD patients is the ability to give larger doses at once to reduce the number of patient visits, a feature that AMAG Pharmaceuticals may be able to capitalize on with Ferumoxytol, an IV iron product currently under review by the FDA.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading ... to the North American healthcare market. , Aerocom Healthcare, LLC will be based ... company will provide new pneumatic tube systems or expand existing systems within the ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):